Pelthos Therapeutics Inc. SEC filings PTHS
Pelthos Therapeutics Inc. has 253 filings in SEC EDGAR's recent list, going back to Sep 6, 2022. Its latest annual report, Form ARS, was filed on Aug 18, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 30, 2026 (material agreement, new debt, unregistered share sale, change to shareholder rights, officer or director change, bylaw or fiscal year change, shareholder vote results, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale, Change to shareholder rights, Officer or director change, Bylaw or fiscal year change, Shareholder vote results, Regulation FD disclosure
|
Oct 30, 2026 | Oct 30, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Oct 1, 2026 | Sep 29, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Restatement
|
Aug 13, 2026 | Aug 12, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
May 28, 2026 | May 28, 2026 |
| 8-K |
Current report
Auditor change, Officer or director change
|
May 21, 2026 | May 15, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 14, 2026 | May 14, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 14, 2026 | Apr 14, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Apr 10, 2026 | Apr 10, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Mar 19, 2026 | Mar 19, 2026 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale, Regulation FD disclosure
|
Jan 13, 2026 | Jan 12, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jan 12, 2026 | Jan 6, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Jan 2, 2026 | Dec 23, 2025 |
| 8-K |
Current report
Officer or director change, Other events
|
Dec 23, 2025 | Dec 23, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Dec 17, 2025 | Dec 17, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 13, 2025 | Nov 13, 2025 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale, Other events
|
Nov 7, 2025 | Nov 7, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 14, 2025 | Oct 14, 2025 |
| 8-K/A |
Amended current report
Acquisition or sale of assets, Results of operations
|
Sep 16, 2025 | Sep 16, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 3, 2025 | Sep 2, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 18, 2025 | Aug 18, 2025 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, New debt, Unregistered share sale, Change to shareholder rights, Change in control, Officer or director change, Bylaw or fiscal year change, Other events
|
Jul 2, 2025 | Jul 1, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
May 1, 2025 | May 1, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Auditor change, Shareholder vote results, Regulation FD disclosure, Other events
|
Apr 17, 2025 | Apr 17, 2025 |
| 8-K |
Current report
Material agreement, New debt
|
Mar 3, 2025 | Feb 25, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Nov 21, 2024 | Nov 21, 2024 |
| 8-K |
Current report
Material agreement, New debt, Change to shareholder rights, Officer or director change, Bylaw or fiscal year change
|
Nov 18, 2024 | Nov 18, 2024 |
| 8-K |
Current report
Shareholder vote results, Other events
|
Oct 24, 2024 | Oct 22, 2024 |
| 8-K |
Current report
Other events
|
Aug 7, 2024 | Aug 5, 2024 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale, Regulation FD disclosure, Other events
|
Jul 29, 2024 | Jul 24, 2024 |
| 8-K |
Current report
Other events
|
Apr 9, 2024 | Apr 9, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 21, 2024 | Mar 21, 2024 |
| 8-K |
Current report
Officer or director change, Other events
|
Mar 18, 2024 | Mar 13, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 13, 2024 | Mar 13, 2024 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Bylaw or fiscal year change, Other events
|
Feb 22, 2024 | Feb 15, 2024 |
Showing 35 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- PTHS (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Durham, NC
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1919246
- Former names
- Channel Therapeutics Corp (until May 27, 2025); Chromocell Therapeutics Corp (until Nov 15, 2024)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.